Clinical efficacy of hyperthermic intraperitoneal chemotherapy combined with photodynamic therapy in the treatment of primary and secondary peritoneal metastases

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076846

Enrollment

Unknown

Registered

2023-10-22

Start date

2023-10-23

Completion date

Unknown

Last updated

2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary and secondary peritoneal metastases

Interventions

one:only HIPEC

two:only intraoperative PDT

three:HIPEC plus intraoperative PDT

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients of both genders, aged =18 years old, were diagnosed with primary or secondary peritoneal metastases (investigational treatment of gastric cancer, colorectal cancer, malignant peritoneal mesothelioma, peritoneal pseudomyxoma, cancerous ascites, peritoneal implantation and metastasis of other malignant tumors, and prevention of peritoneal implantation and metastasis after radical resection of advanced gastric cancer and colorectal cancer).

Exclusion criteria

Exclusion criteria: Patients who had the following conditions could not participate in the study: intestinal obstruction; There was extensive adhesion in the peritoneal cavity. There was obvious inflammation in the abdominal cavity. There are high risk factors for poor anastomotic healing, including anastomotic edema, ischemia, obvious tension, and severe hypoproteinemia. Major organ dysfunction such as heart, kidney, liver and brain; Cachexia; Severe bleeding and coagulation disorders; Patients allergic to photosensitizers; Patients with severe or uncontrolled cardiovascular and pulmonary diseases, or unstable vital signs due to various reasons; Original hematoporphyria or associated with other diseases aggravated by light, such as systemic lupus erythematosus, dermatomyositis, etc. Patients with eye diseases who need to undergo an ophthalmic light examination in the past one month; Use with caution in pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
overall survival;progression free survival;Histopathological types;Tumor markers;TNM staging;IMAGING STUDIES results;Tumor markers;immunological markers;	—

Secondary

Measure	Time frame
clinical manifestations;blood routine examination;kidney function;liver function;	—

Countries

China

Contacts

Public ContactHao Chen

Second Hospital of Lanzhou University

ery_chenh@lzu.edu.cn+86 150 0946 7790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026